@entity14136 ( @entity14136 ), a disorder associated with @entity249 , is treated with @entity251 replacement therapy (TRT) and/or gonadotropins replacement therapy (GRT) (TRT and GRT, together with HRT hormone replacement therapy). In Japan, guidelines have been set for treatment during adolescence. Due to the risk of rapid maturation of bone age, low doses of @entity251 or gonadotropins have been used. However, the optimal timing and methods of therapeutic intervention have not yet been established. The objective of this study was to investigate the current situation of treatment for @entity1 with @entity14136 in Japan and to review a primary survey involving councilors of the Japanese Society for Pediatric Endocrinology and a secondary survey obtained from 26 facilities conducting HRT. The subjects were 55 @entity1 with @entity14136 who reached their adult height after HRT. The breakdown of the @entity1 is as follows: 7 @entity1 with @entity12608 , 6 @entity1 with @entity7103 , 18 @entity1 with acquired @entity4614 due to intracranial and @entity977 , 22 @entity1 with classical @entity4614 due to breech delivery, and 2 @entity1 with @entity11339 . The mean age at the start of HRT was 15.7 yrs and mean height was 157.2 cm. The mean age at reaching adult height was 19.4 yrs, and the mean adult height was 171.0 cm. The starting age of HRT was later than the normal pubertal age and showed a significant negative correlation with pubertal height gain, but it showed no correlation with adult height. As for spermatogenesis, 76% of the above @entity1 treated with hCG-rFSH combined therapy showed positive results, though ranging in levels; impaired spermatogenesis was observed in some with congenital @entity14136 , and favorable spermatogenesis was observed in all with acquired @entity14136 . From the above, we propose the establishment of a treatment protocol for the start low-dose @entity251 or low-dose gonadotropins by dividing subjects into two groups to determine different treatment protocols, acquired and congenital @entity14136 , and to conduct them at a timing closer to the onset of puberty, namely, at a timing near entrance to junior high school. We also propose a new HRT protocol using preemptive FSH therapy prior to GRT aimed at achieving future fertility in @entity1 with congenital @entity14136 .

Treatment situation of male hypogonadotropic hypogonadism in pediatrics and proposal of XXXX and gonadotropins replacement therapy protocols.

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity7103 :: ('MESH:C535764', 'Disease') :: ['isolated gonadotropin deficiency'] @entity11339 :: ('MESH:D058747', 'Disease') :: ['CHARGE syndrome'] @entity4614 :: ('MESH:D007018', 'Disease') :: ['idiopathic hypopituitarism', 'hypopituitarism'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary tumor'] @entity12608 :: ('MESH:D017436', 'Disease') :: ['Kallmann syndrome'] @entity14136 :: ('MESH:D005058', 'Disease') :: ['Male hypogonadotropic hypogonadism', 'MHH']
@entity251 :: (MESH:D013739,Chemical) :: ['testosterone']
